Tag:

Merck

Latest Headlines

Latest Headlines

UPDATED: Merck beefs up its cancer drug pipeline in $375M OncoEthix buyout

Further beefing up its rapidly growing pipeline for new cancer drugs, Merck has stepped in to buy out Switzerland's OncoEthix in a deal worth upward of $375 million. And the Big Pharma player is paying a hefty premium for a BET inhibitor that was in-licensed from Mitsubishi Tanabe just two years ago.

Merck's next-gen Gardasil wins FDA approval

Merck's Gardasil follow-up is here, meaning blockbuster sales are likely on the way. But they'll come at the expense of the previous iteration.

Merck wins FDA approval for Gardasil's heir

Merck won the FDA's blessing for a next-generation HPV vaccine designed to usurp Gardasil, putting it in line for billions in revenue.

Merck hits a hiccup with its new Ebola vaccine

Investigators have suspended a Phase I study of NewLink Genetics' Ebola virus vaccine just weeks after Merck stepped in to license it, citing a safety issue that could delay the pharma giant's plans to quickly ramp up production.

Indonesia's Indofarma combines its manufacturing expertise with Kimia's supply chain strength

Indonesia is one of those emerging markets that has pressured outside companies to produce locally and companies like Pfizer, Merck and Fresenius Kabi have all built or expanded plants there in recent years. But the government, which controls some of the players, is taking steps to improve efficiency in the domestic market, pushing for a merger that ties the manufacturing expertise of one company to the supply chain strength of another.

Merck wins FDA approval for Gardasil follow-up

Merck's Gardasil follow-up is here, meaning blockbuster sales figures are likely on the way. But the bad news is that they'll come at the expense of the world's second-best-selling shot.

Merck Vaccines president Gerberding leaving post for EVP role

Julie Gerberding, president of Merck's vaccines unit, will be moving on come mid-December for a new role as executive vice president for strategic communications, global public policy and population health, the company announced Wednesday.

Merck shows PD-1's promise in breast cancer with positive early results

Merck's pembrolizumab, sold as Keytruda, showed promising signs of efficacy in a particularly deadly brand of breast cancer, early data that could expand the use for a new class of treatments expected to take the market by storm.

Looking for a bright side to the Merck-Cubist merger? It's the power of the sales rep

Some analysts have pointed to Merck's hospital sales force and its 2,000 or so reps. Surely those experienced sales types can wring more sales out of Cubist's products than the much smaller Cubist group did.

Amgen and Merck kick off a combo cancer trial

Amgen and Merck have launched an early-stage trial pairing their respective cancer immunotherapies, looking to confirm the clinical and commercial promise of combination approaches to cancer.